BOSTON, ON, June 18, 2012 /CNW Telbec/ - Together with key partners from
Ontario, the Québec Consortium for Drug Discovery (CQDM) is creating a
new initiative to fund collaborative life sciences research projects
between the two provinces.
This initiative is the first notable and concrete realization of the
Ontario-Québec Life Sciences Corridor, announced at the 2011 BIO
International Convention. It builds upon two previous pilot projects
and existing strengths within the two provinces to increase innovation,
productivity, investment and job creation.
CQDM is partnering with three leading Ontario organizations: MaRS
Innovation (MI), Ontario Brain Institute (OBI) and Ontario Centres of
Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program,
which will support collaborative research projects that seek to develop
new tools for biopharmaceutical research.
"This initiative will help deliver on the potential of the
Ontario-Québec Life Sciences Corridor, and build on the reputation of
the life sciences industries in Canada's two largest provinces," said
Ontario Minister of Economic Development and Innovation Brad Duguid.
"That means new opportunities for innovation, investment and job
creation that will benefit all Canadians."
"The Ontario-Québec Life Sciences Corridor is paving the way for new and
unique opportunities for investments, partnerships and collaborations
in Life Sciences research, innovation and commercialization," said Max
Fehlmann, president and CEO at CQDM. "Ontario and Québec are well
recognized for the excellence of their research and their capacity to
innovate. Our partnership with OCE, OBI and MI will foster innovation
and competitiveness in the Life Sciences sector."
"MaRS Innovation joins with CQDM, OBI and OCE in welcoming this
partnership and the Life Sciences research that it will support," said
Raphael Hofstein, president and CEO of MaRS Innovation. "We anticipate
that this funding program, like the pilot project we co-led with CQDM
to create Encycle Therapeutics, will lead to many similarly successful
"We are pleased to partner with CQDM and look forward to working with
them in funding joint Ontario-Québec neuroscience projects," said Dr.
Don Stuss, president and scientific director of the Ontario Brain
Institute. "This paradigm of having industry partnering with research
excellence to drive viable patient-based outcomes fits nicely the OBI
vision and mandate."
"Ontario Centres of Excellence is pleased to support this important
partnership," said Dr. Tom Corr, president and CEO, Ontario Centres of
Excellence. "By cultivating partnerships within our academic and
industry network, and providing expertise in mentoring and project
proposal preparation, candidates will be well-positioned to further
develop their ideas to enable growth and innovation across the
Ontario-Québec Life Sciences Corridor."
"Québec and Ontario are lead actors in the life sciences sector, a field
with much promise. We have put in place measures to respond to the
needs of our businesses and our researchers in that field. The projects
announced today fully accord with this vision and contribute to our
efforts to bring together the advantages of our two provinces",
commented the Québec Minister of Economic Development, Innovation and
Export Trade Sam Hamad.
This new program is open to all researchers in Québec and Ontario from
academic institutions or small- to medium-sized enterprises (SMEs).
Selected projects will be eligible for up to $750K in funding for three
years. CQDM will fund the Québec arm of the project. While the research
being performed in Ontario may be funded by many different sources,
OBI, OCE or MaRS Innovation will work with Ontario-based partners to
secure funding and will also provide support in preparing projects.
Detailed information about the Québec/Ontario CQDM funding program is available on CQDM's website at www.cqdm.org.
About the CQDM
The Québec Consortium for Drug Discovery (CQDM) is a meeting ground for
all stakeholders in biopharmaceutical research. Its principal mission
is to fund research projects carried out in partnership between the
academic and hospital milieus in the public sector and the
pharmaceutical and biotechnology industries in the private sector. An
innovative Canadian initiative, the CQDM has a twofold goal: to
accelerate the drug discovery process and to develop safer and more
effective drugs. CQDM is funded through contributions from Pfizer
Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd.,
GlaxoSmithKline, Eli Lilly Canada Inc., the Business-Led Networks of
Centres of Excellence (BL-NCE), the Ministère du Développement
Économique, de l'Innovation et de l'Exportation (MDEIE) du Québec and
the Fonds de recherche Québec - Santé (FRQS). For more information: www.cqdm.org.
About MaRS Innovation
MaRS Innovation (MI) is the commercialization agent for the exceptional discovery
pipeline from 16 leading Ontario academic institutions. As a
single-entry point to total member research activity of $1B in annual
research and development, MI provides an easy gateway for investors and
licensees who wish to gain access to technology assets in Ontario.
Supported by the Government of Canada through the Networks of Centres
of Excellence, by the Government of Ontario through the Ontario Centres
of Excellence, and by its member institutions, MI is a transformational
partnership that turns research strengths into real commercial
opportunities. MI's portfolio includes the most promising assets and
advances commercialization into global markets through industry
partnerships, licensing and company creation.
About Ontario Brain Institute
Launched in November 2010, the OBI has been established to become an
internationally recognized centre of excellence in brain research,
translation and innovation. It will achieve its vision by initiating,
funding, promoting and stimulating brain research, education and
training. The research outcomes will be translated into clinical
applications and commercialization opportunities related to the
prevention, early diagnosis, treatment and management of brain diseases
and disorders. The Institute is an independent, not-for-profit
corporation funded by the Government of Ontario. The OBI will serve as
a nexus for collaborative efforts, with a program focused on bringing
together Ontario's leading scientists and clinicians drawn from
Ontario's universities, colleges, and hospitals. For additional
information about the OBI, please visit: http://www.braininstitute.ca/
About Ontario Centres of Excellence (www.oce-ontario.org)
Ontario Centres of Excellence (OCE) drives the commercialization of
cutting-edge research across key market sectors to build the economy of
tomorrow and secure Ontario's global competitiveness. In doing this,
OCE fosters the training and development of the next generation of
innovators and entrepreneurs and is a key partner with Ontario's
industry, universities, colleges, research hospitals, investors and
governments. A champion of leading-edge technologies, best practices
and research, OCE invests in sectors such as advanced health, digital
media and information communications, advanced manufacturing and
materials, and cleantech including energy, environment and water. OCE
through its Centre for Commercialization of Research (CCR), an
initiative supported by the federal government, also acts as a catalyst
which allows innovative businesses to grow and achieve sustainable
commercial success and global competitiveness. OCE is a key partner in
delivering Ontario's Innovation Agenda as a member of the province's
Ontario Network of Excellence (ONE). Funded by the Government of
Ontario, the ONE is Ontario's innovation system. The ONE is made up of
regional and sector focused organizations designed to help
Ontario-based entrepreneurs rapidly grow their companies, and create
jobs. For more information visit www.oneinnovation.ca.
For further information:
Vice-President, Research and Business Development
Marketing and Communications Manager
Ontario Brain Institute
Senior Manager, Media Relations
Ontario Centres of Excellence